Analex Receives New NASA Tasks On Orbital Space Plane
Analex Corporation
announced it has received new tasks to provide professional and
engineering services to the National Aeronautics and Space Administration
(NASA) on the Orbital Space Plane (OSP) project. These tasks will total
approximately $2 million in additional funding under the Company’s Expendable
Launch Vehicle Integrated Services (ELVIS) Contract, in support of the NASA’s
Launch Services Program Office.
The Orbital Space Plane project represents a next generation system of
space vehicles being designed to provide crew rescue and crew transport to and
from the International Space Station, and to transport crews to and from
orbit.
The new tasks under this award include mission analysis, systems
engineering, and special studies aimed at assessing the acceptability of
launching the OSP onboard current Evolved Expendable Launch Vehicles (EELV’s).
Also included are engineering support to specific OSP working groups; in-house
independent model development for basic launch vehicles; and general
engineering / mission analysis support for reliability enhancement and human
rating aspects of EELV’s as a launch service for OSP. There is a fifteen
month period of performance for these tasks.
Analex’s President and Chief Executive Officer, Sterling Phillips, said,
“We are very pleased to support NASA in the development of its next generation
of space exploration.” He added, “Analex remains committed to delivering the
highest possible caliber of support on every aspect of our work for NASA.”
Analex specializes in providing intelligence, systems engineering and
biodefense services in support of our nation’s security. Analex focuses on
developing innovative technical approaches for the intelligence community,
analyzing and supporting defense systems, designing, developing and testing
aerospace systems and developing medical defenses and treatments for
infectious agents used in biological warfare and terrorism. The company’s
stock trades on the American Stock Exchange under the symbol NLX. The
company can be found on the Internet at www.analex.com. Analex investor
relations can be contacted at 703-329-9400 or via email at
amber.gordon@analex.com.
PLEASE NOTE: Except for the historical information contained herein, this
press release contains forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, that involve a
number of risks and uncertainties. These forward-looking statements may be
identified by reference to a future period by use of forward-looking
terminology such as “anticipate,” “expect,” “could,” “intend,” “may” and other
words of a similar nature. There are certain important factors and risks that
could cause results to differ materially from those anticipated by the
statements contained herein. Such factors and risks include business
conditions and growth in the medical research, pharmaceutical and government
contracting arenas and in the economy in general. Competitive factors include
the pressures toward consolidation of small government contracts into larger
contracts awarded to major, multi-national corporations; and the Company’s
ability to continue to recruit and retain highly skilled scientific,
technical, managerial and sales/marketing personnel. Other risks may be
detailed from time to time in the Company’s filings with the Securities and
Exchange Commission. Analex undertakes no obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.
